According to Healios’ CEO Hardy TS KAGIMOTO, Helios plans to start clinical trials with iPS-derived RPE in 2017 and hopes for approval in 2020. For international trials, cooperation with Lonza is envisioned. Nikkei Biotech news release, June 30, 2015
The 800 m2 two story laboratory will be located in Nakagami, Okinawa, and focus on adipose stem cells, using serum-free media technology for expansion. R&D is done in collaboration with the University of the Ryukyus. Rohto press release, June 26, 2015
The system with a photovoltaic power generation of 30 kW and 60 L/h of hot water supply has a hydrogen electric power storate capacity of 350 kWh. One of the applications of H2One is response to disasters: after a natural disaster, the system will be transported by...
„ReproNaive™“ is a medium component which keeps iPS cells in the naive (unprimed) state for at least 10 days. It was developed by Naoki NISHISHITA at the Kobe Foundation for Biomedical Research and Innovation who is also Adviser to ReproCell. It will be sold from July...
The sales of Euglena-related products were 2,7 billion Yen in 2014, of which 80 % was in yoghurts, drinks and other health food, and the remainder in cosmetics. The products are mostly sold by the internet. Fuji Economy „2015 edition of useful biological components...
